Celgene's most recent trend suggests a bullish bias. One trading opportunity on Celgene is a Bull Put Spread using a strike $90.00 short put and a strike $85.00 long put offers a potential 31.23% return on risk over the next 32 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $90.00 by expiration. The full premium credit of $1.19 would be kept by the premium seller. The risk of $3.81 would be incurred if the stock dropped below the $85.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Celgene is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Celgene is bullish.
The RSI indicator is at 62.84 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Celgene
UK cost agency backs Celgene bone marrow drug in change of tack
Tue, 19 Aug 2014 23:01:00 GMT
Reuters – Celgene's drug Revlimid should be an option on Britain's state health service for patients with serious bone marrow disorders and a specific chromosomal abnormality, the country's cost agency said on Wednesday. The final draft guidance from the National Institute for Health and Care Excellence (NICE) represents a change of tack after the medicine was rejected last year for treating myelodysplastic syndromes, which can lead to life-threatening diseases including leukaemia. The latest decision follows the submission of revised analyses from Celgene and further information on the company's proposal to limit the cost of the drug. Celgene has agreed to provide Revlimid free of charge for anyone who needs more than 26 monthly cycles of treatment.
7:31 am Celgene: clinical study in the Journal of Clinical Oncology reports patients with diffuse large b-cell lymphoma receiving oral REVLIMID with standard R-CHOP achieved 98% overall response rate and 80% complete response rate
Tue, 19 Aug 2014 11:31:00 GMT
Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate
Tue, 19 Aug 2014 11:30:00 GMT
Business Wire – Celgene Corporation today announced that results of a study evaluating the combination of REVLIMID® with rituximab, cyclophosphamide, doxorubicin hydro
Hot biotech drugs
Tue, 19 Aug 2014 11:07:00 GMT
Jazz, Celgene Lead Top 4 Drugmaker Profit Margins
Mon, 18 Aug 2014 17:46:00 GMT
Related Posts
Also on Market Tamer…
Follow Us on Facebook